IMPROVED INFARCT-RELATED ARTERIAL PATENCY AFTER HIGH-DOSE, WEIGHT-ADJUSTED, RAPID INFUSION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN MYOCARDIAL-INFARCTION - RESULTS OF A MULTICENTER RANDOMIZED TRIAL OF 2 DOSAGE REGIMENS

To determine whether a weight-adjusted high dose (2 mg/kg body weight over 3 h) rapid infusion of recombinant tissue-type plasminogen activator (rt-PA) was more efficacious than a weight-adjusted standard dose (1.25 mg/kg over 3 h) in achieving reperfusion in the setting of acute myocardial infarction, 175 patients were entered into a randomized multicenter trial. Eighty-four patients were entered into the high dose group, receiving 1.2 mg/kg (10% given as a bolus injection) over 1 h, followed by 0.8 mg/kg over the next 2 h. Ninety-one patients were given 0.75 mg/kg (10% given as a bolus injection) in 1 h, followed by 0.5 mg/kg administered over the next 2 h. The median dose in the group that received 2 mg/kg dose was 145 mg, compared with 100 mg in the group that received 1.25 mg/kg. The 90 min patency rate in the group that received 2 mg/kg was 84% compared with 70% in the group that received 1.25 mg/kg (p = 0.003). Sixty-four percent of the patients in each group underwent coronary angioplasty at the time of cardiac catheterization. The infarct-related artery patency rate at the end of catheterization was 91% in the group that received 2 mg/kg compared with 83% in the group that received 1.25 mg/kg (p = 0.08). Among patients with a patent infarct-related coronary artery after catheterization, the 6 month mortality rate in the group that received 2 mg/kg was 2.9% compared with 9.8% in the group that received 1.25 mg/kg (p = 0.15). The bleeding complication rate in the two groups was similar. Two patients in the group that received 2 mg/kg developed nonfatal intracranial bleeding (one after emergency open heart surgery). These data suggest that more rapid administration of a higher weight-adjusted dose of rt-PA may be more effective in restoring infarct-related artery patency in the setting of acute myocardial Infarction than the currently accepted dose of 100 mg over 3 h. Larger randomized trials are warranted to evaluate the need for prolonged (>60 to 90 min) infusions, optimal dosage and the risk of intracranial bleeding with more rapid rt-PA administration. © 1990.